Call Us: +44 (0) 1752 753723[email protected]

16
Jul

The latest clinical trial to explore the therapeutic potential of cord blood launched this month with a focus on autism. In recent years the number of children with autism has been rising, and no one knows why. A few months ago the Center for Disease Control and Prevention upgraded the prevalence of autism in children age eight from 1 in 88 to 1 in 68; among boys the prevalence is 1 in 42.

Duke Medical Center in Durham, North Carolina, USA will be performing the trial. The trial proposal states: “In this (autism) study, the investigators hypothesize that infusion of a patient’s own umbilical cord blood cells can offer neural protection/repair in the brain and reduction of inflammation associated with this (autism) disorder.”

The new autism trial will look at the safety and efficacy of giving their own cord blood to 20 children between ages 2 and 6 years. This trial is open to any child, worldwide, who has their own cord blood in storage and meets the trial criteria. There is no control group in this trial, every child will receive the stem cell therapy and then have follow ups at 6 and 12 months. That being said, the first children going into treatment have been on a waiting list, so new applicants will have to wait for the next autism trial.

For more information click here.